Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Keine aktuellen Veranstaltungen.
Vergangene Veranstaltungen (max. 10)
-
2023 WS
-
2023 SS
-
2022 WS
-
2022 SS
-
2021 WS
-
2021 SS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
CD8⁺ CD28⁻ regulatory T cells after induction therapy predict progression-free survival in myeloma patients : Results from the GMMG-HD6 multicenter phase III studyIn: Leukemia Jg. 38 (2024) Nr. 7, S. 1621 - 1625Online Volltext: dx.doi.org/ (Open Access)
-
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13) : 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.In: The Lancet Oncology Jg. 25 (2024) Nr. 6, S. 744 - 759Online Volltext: dx.doi.org/ (Open Access)
-
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma : Data from five randomized, controlled, phase III trials in 3700 patientsIn: Leukemia Jg. 38 (2024) Nr. 3, S. 640 - 647Online Volltext: dx.doi.org/ (Open Access)
-
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MMIn: Blood Advances Jg. 7 (2023) Nr. 3, S. 379 - 383Online Volltext: dx.doi.org/ (Open Access)
-
Final analysis of the CLL2-GIVe trial : obinutuzumab, ibrutinib and venetoclax in untreated CLL with del(17p)/TP53mutIn: Blood Jg. 142 (2023) Nr. 11, S. 961 - 972Online Volltext: dx.doi.org/
-
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma : Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma NetworkIn: Journal of Clinical Oncology (JCO) Jg. 41 (2023) Nr. 3, S. 479 - 484Online Volltext: dx.doi.org/
-
Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphomaIn: Annals of Hematology Jg. 102 (2023) Nr. 12, S. 3445 - 3455Online Volltext: dx.doi.org/ (Open Access)
-
Publisher Correction: Epigenome-wide analysis of T-cell large granular lymphocytic leukemia identifies BCL11B as a potential biomarkerIn: Clinical Epigenetics Jg. 15 (2023) Nr. 1, 3Online Volltext: dx.doi.org/ (Open Access)
-
A genetic risk score of alleles related to MGUS interacts with socioeconomic position in a population-based cohortIn: Scientific Reports Jg. 12 (2022) Nr. 1, 4409Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7) : Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialIn: The Lancet Haematology Jg. 9 (2022) Nr. 11, S. e810 - e821Online Volltext: dx.doi.org/
-
Epigenome-wide analysis of T-cell large granular lymphocytic leukemia identifies BCL11B as a potential biomarkerIn: Clinical Epigenetics Jg. 14 (2022) Nr. 1, 148Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma : First analysis of toxicity and efficacy signalsIn: Leukemia and Lymphoma Jg. 63 (2022) Nr. 1, S. 84 - 92Online Volltext: dx.doi.org/
-
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemiaIn: Blood Jg. 139 (2022) Nr. 9, S. 1318 - 1329Online Volltext: dx.doi.org/ (Open Access)
-
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristicsIn: European Journal of Haematology Jg. 108 (2022) Nr. 1, S. 73 - 83Online Volltext: dx.doi.org/ (Open Access)
-
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma : A European Myeloma Network (EMN) Report Within the HARMONY ProjectIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 29, S. 3406 - 3418Online Volltext: dx.doi.org/ (Open Access)
-
Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma : Final results of the non‐interventional study MabSCaleIn: Cancer Medicine Jg. 12 (2022) Nr. 3, S. 2739 - 2751Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
T-cell prolymphocytic leukemia is associated with deregulation of oncogenic microRNAs on transcriptional and epigenetic levelIn: Genes, Chromosomes and Cancer Jg. 61 (2022) Nr. 7, S. 432 - 436Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Air pollution and polyclonal elevation of serum free light chains : An assessment of adaptive immune responses in the prospective heinz nixdorf recall studyIn: Environmental Health Perspectives Jg. 129 (2021) Nr. 2, S. 027004Online Volltext: dx.doi.org/ (Open Access)
-
Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia : Primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)In: Haematologica / The Hematology Journal Jg. 106 (2021) Nr. 2, S. 543 - 554Online Volltext: dx.doi.org/ (Open Access)
-
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageIn: Leukemia Jg. 35 (2021) Nr. 3, S. 809 - 822Online Volltext: dx.doi.org/ (Open Access)
-
Human cord blood b cells differ from the adult counterpart by conserved ig repertoires and accelerated response dynamicsIn: The Journal of Immunology (JI) Jg. 206 (2021) Nr. 12, S. 2839 - 2851Online Volltext: dx.doi.org/ (Open Access)
-
Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvementIn: European Journal of Haematology Jg. 107 (2021) Nr. 4, S. 449 - 457Online Volltext: dx.doi.org/ (Open Access)
-
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaIn: Blood Cancer Journal Jg. 11 (2021) Nr. 1, S. 1Online Volltext: dx.doi.org/ (Open Access)
-
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III TrialIn: Leukemia (2021)Online Volltext: dx.doi.org/
-
Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort studyIn: Scientific Reports Jg. 11 (2021) Nr. 1, 19266Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Prognostic impact of serum free light chain ratio normalization in patients with multiple myeloma treated within the GMMG-MM5 trialIn: Cancers Jg. 13 (2021) Nr. 19, 4856Online Volltext: dx.doi.org/ (Open Access)
-
Proteomic and bioinformatic profiling of neutrophils in CLL reveals functional defects that predispose to bacterial infectionsIn: Blood Advances Jg. 5 (2021) Nr. 5, S. 1259 - 1272Online Volltext: dx.doi.org/ (Open Access)
-
Publisher Correction : Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageIn: Leukemia Jg. 35 (2021) Nr. 12, S. 3636Online Volltext: dx.doi.org/ (Open Access)
-
Richter transformation in chronic lymphocytic leukemia (CLL) : a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trialsIn: Leukemia Jg. 35 (2021) Nr. 1, S. 169 - 176Online Volltext: dx.doi.org/
-
Selective elimination of immunosuppressive T cells in patients with multiple myelomaIn: Leukemia Jg. 35 (2021) Nr. 9, S. 2602 - 2615Online Volltext: dx.doi.org/ (Open Access)
-
Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemiaIn: Therapeutic Advances in Hematology Jg. 11 (2020) S. 1 - 15Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
CpG stimulation of chronic lymphocytic leukemia cells induces a polarized cell shape and promotes migration in vitro and in vivoIn: PLoS ONE Jg. 15 (2020) Nr. 2, S. e0228674Online Volltext: dx.doi.org/ (Open Access)
-
Identifying genetic lesions in ocular adnexal extranodal marginal zone lymphomas of the malt subtype by whole genome, whole exome and targeted sequencingIn: Cancers Jg. 12 (2020) Nr. 4, S. 986Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemiaIn: European Journal of Haematology Jg. 105 (2020) Nr. 6, S. 786 - 796Online Volltext: dx.doi.org/ (Open Access)
-
Noncanonical effector functions of the T-memory–like T-PLL cell are shaped by cooperative TCL1A and TCR signalingIn: Blood Jg. 136 (2020) Nr. 24, S. 2786 - 2802Online Volltext: dx.doi.org/ (Open Access)
-
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemiaIn: Genes, Chromosomes and Cancer Jg. 59 (2020) Nr. 4, S. 261 - 267Online Volltext: dx.doi.org/ (Open Access)
-
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trialIn: Leukemia Jg. 34 (2020) Nr. 7, S. 1853 - 1865Online Volltext: dx.doi.org/
-
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone : results of the phase II PERSPECTIVE Multiple Myeloma trialIn: Blood Cancer Journal Jg. 9 (2019) Nr. 4, S. 45Online Volltext: dx.doi.org/ (Open Access)
-
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patientsIn: Blood Cancer Journal Jg. 9 (2019) Nr. 2, S. 13Online Volltext: dx.doi.org/ (Open Access)
-
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemiaIn: Leukemia Jg. 33 (2019) Nr. 2, S. 390 - 402Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myelomaIn: Blood Cancer Journal Jg. 9 (2019) Nr. 9, S. 71Online Volltext: dx.doi.org/ (Open Access)
-
Human multipotent hematopoietic progenitor cell expansion is neither supported in endothelial and endothelial/mesenchymal co-cultures nor in NSG miceIn: Scientific Reports Jg. 9 (2019) S. 12914Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLLIn: Cancers Jg. 11 (2019) Nr. 12, S. 1833Online Volltext: dx.doi.org/ (Open Access)
-
New lessons learned in T-PLL : results from a prospective phase-II trial with fludarabine–mitoxantrone–cyclophosphamide–alemtuzumab induction followed by alemtuzumab maintenanceIn: Leukemia and Lymphoma Jg. 60 (2019) Nr. 3, S. 649 - 657Online Volltext: dx.doi.org/
-
Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival
17th International Myeloma Workshop ; September 12-15, 2019, Boston, MA, USA,In: Clinical Lymphoma, Myeloma & Leukemia Jg. 19 (2019) Nr. 10, Suppl., S. e208Online Volltext: dx.doi.org/ -
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6 : A randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaIn: BMC Cancer Jg. 19 (2019) Nr. 1, S. 504Online Volltext: dx.doi.org/ (Open Access)
-
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP : results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trialIn: Annals of Hematology Jg. 98 (2019) Nr. 4, S. 897 - 907Online Volltext: dx.doi.org/
-
Socioeconomic Position is Positively Associated with Monoclonal Gammopathy of Undetermined Significance in a Population-based Cohort StudyIn: Annals of Hematology Jg. 98 (2019) Nr. 12, S. 2761 - 2767Online Volltext: dx.doi.org/
-
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy) : A study protocol for a single-arm, non-randomized, open, national, multi-center phase II trialIn: Trials Jg. 20 (2019) Nr. 1, S. 544Online Volltext: dx.doi.org/ (Open Access)
-
Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus–infected individualsIn: Blood Jg. 131 (2018) Nr. 5, S. 546 - 557Online Volltext: dx.doi.org/ (Open Access)
-
Drug-perturbation-based stratification of blood cancerIn: The Journal of Clinical Investigation (JCI) Jg. 128 (2018) Nr. 1, S. 427 - 445Online Volltext: dx.doi.org/ (Open Access)
-
Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R) : Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)
Society of Hematologic Oncology 6th Annual Meeting (SOHO) ; September 12-15, 2018, Houston, Texas, USA,In: Clinical Lymphoma, Myeloma & Leukemia Jg. 18 (2018) Nr. Suppl. 1, S. S101 - S103Online Volltext: dx.doi.org/ -
Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study : Influence of chemotherapy on efficacy and safetyIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 23, S. 2395 - 2404Online Volltext: dx.doi.org/ (Open Access)
-
Light chain monoclonal gammopathy of undetermined significance is characterized by a high disappearance rate and low risk of progression on longitudinal analysisIn: Annals of Hematology Jg. 97 (2018) Nr. 8, S. 1463 - 1469Online Volltext: dx.doi.org/
-
Magnetic resonance imaging before and after upfront autologous transplantation identifies patients with adverse outcome but response to treatment within the prospective GMMG MM5 phase III trialIn: Haematologica / The Hematology Journal Jg. 103 (2018) Nr. Suppl. 1, S. 11 - 12
-
Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemiaIn: Nature Communications Jg. 9 (2018) S. 3839Online Volltext: dx.doi.org/ (Open Access)
-
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) : A Multicenter, Randomized Phase III TrialIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 20, S. 2024 - 2034Online Volltext: dx.doi.org/ (Open Access)
-
Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemiaIn: OncoTarget Jg. 9 (2018) Nr. 41, S. 26353 - 26369Online Volltext: dx.doi.org/ (Open Access)
-
Rituximab with Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma : Results of the MIR StudyIn: HemaSphere: Open Access Journal of the European Hematology Association Jg. 2 (2018) Nr. 6, S. e160Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemiaIn: Blood Cancer Journal Jg. 8 (2018) Nr. 1, S. 11Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myelomaIn: OncoImmunology Jg. 7 (2018) Nr. 10, e1486356Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapyIn: Leukemia and Lymphoma Jg. 58 (2017) Nr. 2, S. 348 - 356Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trialIn: Bone Marrow Transplantation Jg. 52 (2017) Nr. 8, S. 1194 - 1198Online Volltext: dx.doi.org/ (Open Access)
-
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trialIn: OncoTarget Jg. 8 (2017) Nr. 49, S. 84847 - 84862Online Volltext: dx.doi.org/ (Open Access)
-
HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemiaIn: Cancer Jg. 123 (2017) Nr. 5, S. 814 - 823Online Volltext: dx.doi.org/
-
Immunochemotherapy with obinutuzumab or rituximab in previously untreated follicular lymphoma in the randomized phase III gallium study : analysis by chemotherapy regimenIn: Haematologica / The Hematology Journal Jg. 102 (2017) Nr. Suppl. 2, S. 314
-
Is long-term particulate matter and nitrogen dioxide air pollution associated with incident monoclonal gammopathy of undetermined significance (MGUS)? : An analysis of the Heinz Nixdorf Recall studyIn: Environment International Jg. 108 (2017) S. 237 - 245Online Volltext: dx.doi.org/
-
Longitudinal analysis of light-chain monoclonal gammopathy of undetermined significance-10-year follow up of the population-based Heinz Nixdorf Recall studyIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3, S. 81 Abstract P292Online Volltext: dx.doi.org/
-
NOTCH-signaling in the tumor microenvironment is required for canonical WNT signaling in CLL cellsIn: Leukemia and Lymphoma Jg. 58 (2017) Nr. Suppl. 1, XVII International Workshop on Chronic Lymphocytic Leukemia 2017 May 12--15, 2017, New York, S. 125 - 126Online Volltext: dx.doi.org/
-
Successful treatment of cerebral aspergillosis: Case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL)In: BMC Infectious Diseases Jg. 17 (2017) S. 797Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Tumor-derived exosomes modulate PD-L1 expression in monocytesIn: Science Immunology Jg. 2 (2017) Nr. 13,Online Volltext: dx.doi.org/
-
Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinationsIn: Leukemia and Lymphoma Jg. 57 (2016) Nr. 9, S. 2235 - 2238Online Volltext: dx.doi.org/
-
Bendamustine triggered paraneoplastic pemphigus in a patient with chronic lymphocytic leukemiaIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 3, S. 257 - 258
-
Chronic Lymphocytic Leukemia-Derived Extracellular Vesicles Mediate NF kappa B Signaling and Pro-Inflammatory Cytokine Release in MonocytesIn: The Journal of Immunology (JI) Jg. 196 (2016) Nr. Suppl. 1, -
-
Chronic lymphocytic leukemia-derived extracellular vesicles mediate NFkB signaling and pro-inflammatory cytokine release in monocytesIn: Cancer Research Jg. 76 15 (2016) -Online Volltext: dx.doi.org/
-
Deorphanization and characterization of the ectopically expressed olfactory receptor OR51B5 in myelogenous leukemia cellsIn: Cell Death Discovery Jg. 2 (2016) Nr. 1, 16010Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia : Results of the CLL9 trial of the German CLL study groupIn: Leukemia and Lymphoma Jg. 57 (2016) Nr. 4, S. 789 - 796Online Volltext: dx.doi.org/
-
Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemiaIn: British Journal of Haematology Jg. 173 (2016) Nr. 2, S. 265 - 273Online Volltext: dx.doi.org/
-
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia : data from the prospective, multicenter phase-II CLL-009 trialIn: Blood Cancer Journal Jg. 6 (2016) S. e404Online Volltext: dx.doi.org/ (Open Access)
-
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trialIn: Haematologica / The Hematology Journal Jg. 101 (2016) Nr. 12, S. e485 - e487Online Volltext: dx.doi.org/ (Open Access)
-
Recurrent alterations of TNFAIP3 (A20) in T-cell large granular lymphocytic leukemiaIn: International Journal of Cancer Jg. 138 (2016) Nr. 1, S. 121 - 124Online Volltext: dx.doi.org/ (Open Access)
-
Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomasIn: OncoTarget Jg. 7 (2016) Nr. 38, S. 62627 - 62639Online Volltext: dx.doi.org/ (Open Access)
-
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trialIn: Leukemia and Lymphoma Jg. 57 (2016) Nr. 6, S. 1291 - 1299Online Volltext: dx.doi.org/
-
Subcutaneous rituximab in patients with DLBCL and follicular NHL - First interim results from the non-interventional study MabSCaleIn: Oncology Research and Treatment Jg. 39 3 (2016) S. 156 - 156
-
Elevated levels of soluble HLA-E and the presence of HLA-E*01:03 predict disease of progression in CLLIn: Tissue Antigens Jg. 86 (2015) Nr. 2, S. 85 - 86
-
Functional abnormalities and changes in gene expression in fibroblasts and macrophages from the bone marrow of patients with acute myeloid leukemiaIn: International Journal of Hematology Jg. 102 (2015) Nr. 3, S. 278 - 288Online Volltext: dx.doi.org/
-
Immunoglobulin M Heavy/Light Chain Pair Measurement Independently Predicts Clinical Outcome and Refines Prognostic Information Provided By Interim PET in Patients with Aggressive LymphomasIn: Blood Jg. 126 (2015) Nr. 23,
-
Multipotent Hematopoietic Progenitors Divide Asymmetrically to Create Progenitors of the Lymphomyeloid and Erythromyeloid LineagesIn: Stem Cell Reports Jg. 5 (2015) Nr. 1, S. 154 - 155Online Volltext: dx.doi.org/ (Open Access)
-
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myelomaIn: Leukemia Jg. 29 (2015) Nr. 8, S. 1721 - 1729Online Volltext: dx.doi.org/
-
Recurrent CDKN1B (p27) mutations in hairy cell leukemiaIn: Blood Jg. 126 (2015) Nr. 8, S. 1005 - 1008Online Volltext: dx.doi.org/
-
Soluble HLA-E and HLA-E polymorphism predictors of early disease progression in CLLIn: Tissue Antigens Jg. 85 (2015) Nr. 5, S. 327 - 328
-
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma : an interim analysis from the prospective GMMG-MM5 trialIn: Haematologica / The Hematology Journal Jg. 100 (2015) Nr. 7, S. 964 - 969Online Volltext: dx.doi.org/ (Open Access)
-
Increases levels of soluble HLA-E are associated with advanced disease stage and early treatment requirement in chronic lymphoytic leukemiaIn: Tissue Antigens Jg. 84 (2014) Nr. 1, S. 139 - 139
-
Multipotent hematopoietic progenitors divide asymmetrically to create progenitors of the lymphomyeloid and erythromyeloid lineagesIn: Stem Cell Reports Jg. 3 (2014) Nr. 6, S. 1058 - 1072Online Volltext: dx.doi.org/ (Open Access)
-
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformationIn: American Journal of Hematology Jg. 89 (2014) Nr. 12, S. E239 - 43Online Volltext: dx.doi.org/ (Open Access)
-
Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial)In: Blood Jg. 124 (2014) Nr. 21, S. 391Online Volltext: dx.doi.org/
-
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemiaIn: Genes, Chromosomes and Cancer Jg. 53 (2014) Nr. 4, S. 309 - 316Online Volltext: dx.doi.org/
-
Systematic mapping of drug sensitivity in hematological malignancies identifies vulnerability of chronic lymphocytic leukemia with mutant p53In: Cancer Research Jg. 74 (2014) Nr. 19 Suppl., S. 5557Online Volltext: dx.doi.org/
-
Bone turnover in multiple myeloma : Impact of bortezomib-based induction therapy, high-dose melphalan, and lenalidomide consolidation on osteoblast and osteoclast function within the GMMG-MM5 trialIn: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 38 - 38
-
CD44 regulates the apoptotic response and promotes disease development in chronic lymphocytic leukemiaIn: Blood Jg. 121 (2013) Nr. 20, S. 4126 - 4136Online Volltext: dx.doi.org/
-
CLL associated immunodeficiencyIn: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 1 - 1
-
Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1(+) effector memory phenotypeIn: Cancer Immunology, Immunotherapy Jg. 62 (2013) Nr. 11, S. 1697 - 1709Online Volltext: dx.doi.org/
-
Gene expression profiling and its arrival in clinical routineIn: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 170 - 170
-
Indolent T-cell lymphomas (T-LGL and others)In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 87 - 87
-
Leukämien : Modellkrankheiten für die Entstehung und Behandlung von KrebsIn: Unikate: Berichte aus Forschung und Lehre (2013) Nr. 44: Medizin : 50 Jahre Universitätsklinikum Essen, S. 114 - 125Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Next generation transcriptome sequencing confirms the presence of somatic STAT3 mutations and identifies novel TNFAIP3 mutations in T Large Granular Lymphocytic Leukemia (T-LGL)In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 196
-
Preclinical testing of a novel Axl-kinase inhibitor in Chronic Lymphocytic LeukemiaIn: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 172 - 172
-
Prevalence and incidence of anemia in the German Heinz Nixdorf Recall StudyIn: Annals of Hematology Jg. 92 (2013) Nr. 6, S. 731 - 737Online Volltext: dx.doi.org/
-
Progranulin Is a Novel Independent Predictor of Disease Progression and Overall Survival in Chronic Lymphocytic LeukemiaIn: PLoS ONE Jg. 23 (2013) Nr. 8, S. e72107Online Volltext: dx.doi.org/ (Open Access)
-
Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivoIn: Cancer Cell Jg. 23 (2013) Nr. 1, S. 77 - 92Online Volltext: dx.doi.org/ (Open Access)
-
Revision of the Human Hematopoietic Tree: Granulocyte Subtypes Derive from Distinct Hematopoietic LineagesIn: Cell Reports Jg. 3 (2013) Nr. 5, S. 1539 - 1552Online Volltext: dx.doi.org/
-
Abundance of a NOTCH1 mutated clone affects clinical outcome of patients with chronic lymphocytic leukemiaIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 97 - 97
-
CLLU1 expression distinguishes chronic lymphocytic leukemia from other mature B-cell neoplasmsIn: Leukemia Research Jg. 36 (2012) Nr. 9, S. 1204 - 1207Online Volltext: dx.doi.org/
-
Cellular origin and pathophysiology of chronic lymphocytic leukemiaIn: Journal of Experimental Medicine (JEM) Jg. 209 (2012) Nr. 12, S. 2183 - 2198Online Volltext: dx.doi.org/ (Open Access)
-
Combined SNP Microarray Based Genomic Mapping and Next Generation Transcriptome Sequencing Confirms the Presence of Somatic STAT3 Mutations and Identifies Novel Chromosomal Imbalances and Candidate Genes in T Large Granular Lymphocytic Leukemia (T-LGL)In: Blood Jg. 120 (2012) Nr. 21, S. 3512Online Volltext: dx.doi.org/
-
Epigenetic Silencing of the Circadian Clock Gene CRY1 is Associated with an Indolent Clinical Course in Chronic Lymphocytic LeukemiaIn: PLoS ONE Jg. 7 (2012) Nr. 12, S. e34347Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of free light-chain abnormalities as prognostic marker in Binet A stage chronic lymphocytic leukemiaIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 99 - 99
-
Functional analyses of human hemtopoietic CD133(+)CD34(+) and CD133(LOW/-)CD34(+) cells challenge the existence of human common myeloid progenitor cellsIn: Experimental Hematology Jg. 40 (2012) Nr. 8, Suppl. 1, S. 124
-
Lipid raft redistribution and morphological cell polarization are separable processes providing a basis for hematopoietic stem and progenitor cell migrationIn: The International Journal of Biochemistry & Cell Biology Jg. 44 (2012) Nr. 7, S. 1121 - 1132Online Volltext: dx.doi.org/
-
Molecular and morphological cell polarizationis required for human hematopoietic stem and progenitor cell migration and homingIn: Experimental Hematology Jg. 40 (2012) Nr. 8, Suppl. 1, S. S106 - S107
-
Preclinical Testing of a Novel Axl-Kinase Inhibitor in Chronic Lymphocytic LeukemiaIn: Blood Jg. 120 (2012) Nr. 21,
-
Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in GermanyIn: Annals of Hematology Jg. 91 (2012) Nr. 2, S. 243 - 248Online Volltext: dx.doi.org/
-
Progranulin plasma concentration is a novel independent prognostic marker in chronic lymphocytic leukemiaIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 100
-
Protein Kinase C-beta Dependent Activation of NF-kappa B in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B-Cells in VivoIn: Blood Jg. 120 (2012) Nr. 21, S. 314
-
Serum immunoglobulin alterations in patients with chronic hepatitis CIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 142 - 143
-
Toll-like receptor 9 agonists induce polarization and migration of chronic lymphocytic leukemia cellsIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 106
-
Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumabIn: Histochemistry and Cell Biology Jg. 137 (2012) Nr. 3, S. 391 - 401Online Volltext: dx.doi.org/
-
p53 protein expression in chronic lymphocytic leukemiaIn: Leukemia and Lymphoma Jg. 53 (2012) Nr. 7, S. 1282 - 1288Online Volltext: dx.doi.org/
-
Association of soluble MICA levels to the MICA-129 polymorphism and treatment free survival in chronic lymphocytic leukaemia patientsIn: Tissue Antigens Jg. 77 (2011) Nr. 5, S. 393 - 393
-
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemiaIn: Blood Jg. 117 (2011) Nr. 24, S. 6450 - 6458Online Volltext: dx.doi.org/
-
Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft modelIn: European Journal of Haematology Jg. 87 (2011) Nr. 1, S. 10 - 19Online Volltext: dx.doi.org/
-
Monoclonal gammopathy of undetermined significance and solid tumor development in the Heinz Nixdorf Recall Study
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 243Online Volltext: dx.doi.org/ -
Novel human bone marrow stroma cell lines from a normal donor and leukemia and lymphoma patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 260Online Volltext: dx.doi.org/ -
Telomeres and prognosis in patients with chronic lymphocytic leukaemiaIn: International Journal of Hematology Jg. 93 (2011) Nr. 1, S. 74 - 82Online Volltext: dx.doi.org/
-
The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemiaIn: Leukemia Jg. 25 (2011) Nr. 4, S. 638 - 647Online Volltext: dx.doi.org/
-
705 Increased prevalence of monoclonal b lymphocytosis in patients with chronic Hepatitis CIn: Journal of Hepatology Jg. 52 (2010) Nr. Suppl. 1, S. S274Online Volltext: dx.doi.org/
-
Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia (CLL)In: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. Suppl. 15, S. 6520Online Volltext: dx.doi.org/
-
Dihydroartemisinin induces apoptosis by a bak-dependent intrinsic pathwayIn: Molecular Cancer Therapeutics Jg. 9 (2010) Nr. 9, S. 2497 - 2510Online Volltext: dx.doi.org/ (Open Access)
-
Gene dosage effects in chronic lymphocytic leukemiaIn: Cancer Genetics and Cytogenetics Jg. 203 (2010) Nr. 2, S. 149 - 160Online Volltext: dx.doi.org/
-
Ofatumumab Combined With Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients With Previously Untreated Chronic Lymphocytic Leukemia : Results From a Randomized, Multicenter, International, Two-Dose, Parallel-Group Phase II TrialIn: Clinical Lymphoma, Myeloma & Leukemia Jg. 10 (2010) Nr. 3, S. E33 - E34Online Volltext: dx.doi.org/
-
Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemiaIn: Leukemia Research Jg. 34 (2010) Nr. 7, S. 892 - 898Online Volltext: dx.doi.org/
-
Prevalence of monoclonal gammopathy of undetermindes significance in a densley populated, highly industrialized area in Germany
15th Congress of the European Hematology Association, Spain, Barcelona, June 10–13, 2010,In: Haematologica, the hematology journal Jg. 95 (2010) Nr. Suppl. 2, S. 394, 0949 -
Prognostic Significance of Molecular Remission in Follicular LymphomaIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. 30, S. e613Online Volltext: dx.doi.org/
-
The impact of CD38 in the CLL NOD/SCID xenograft modelIn: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 200 - 201
-
The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemiaIn: Leukemia Jg. 24 (2010) Nr. 6, S. 1152 - 1159Online Volltext: dx.doi.org/
-
BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemiaIn: Leukemia and Lymphoma Jg. 50 (2009) Nr. 11, S. 1837 - 1842
-
CD4⁺CD25⁺ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosisIn: Nephrology Dialysis Transplantation (NDT) Jg. 24 (2009) Nr. 1, S. 161 - 171Online Volltext: dx.doi.org/ (Open Access)
-
Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemiaIn: European Journal of Haematology Jg. 83 (2009) Nr. 4, S. 320 - 327Online Volltext: dx.doi.org/
-
Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemiaIn: Leukemia Research Jg. 33 (2009) Nr. 6, S. 775 - 778Online Volltext: dx.doi.org/
-
FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemiaIn: European Journal of Haematology Jg. 83 (2009) Nr. 6, S. 541 - 549Online Volltext: dx.doi.org/
-
Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia with TCL1A–TCRAD juxtapositionIn: Cancer Genetics and Cytogenetics Jg. 192 (2009) Nr. 1, S. 44 - 47Online Volltext: dx.doi.org/
-
Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cellsIn: Leukemia Research Jg. 32 (2008) Nr. 10, S. 1565 - 1572Online Volltext: dx.doi.org/
-
A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the diseaseIn: Cancer Research Jg. 67 (2007) Nr. 18, S. 8653 - 8661Online Volltext: dx.doi.org/
-
Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemiaIn: Blood Jg. 109 (2007) Nr. 1, S. 290 - 297Online Volltext: dx.doi.org/
-
Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11q32)In: Leukemia Jg. 21 (2007) Nr. 10, S. 2153 - 2163Online Volltext: dx.doi.org/
-
Short telomeres and high telomerase activity in T-cell prolymphocytic leukemiaIn: Leukemia Jg. 21 (2007) Nr. 12, S. 2456 - 2462Online Volltext: dx.doi.org/
-
Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemiaIn: British Journal of Haematology Jg. 138 (2007) Nr. 2, S. 217 - 220Online Volltext: dx.doi.org/
-
A correction for expression value dependencies in AffymetrixIn: Online Journal of Bioinformatics (OJB) Jg. 7 (2006) Nr. 1, S. 1 - 14
-
Bax gene G(-248)A promoter polymorphism and chronic lymphocytic leukemia: lack of association with incidence, disease stage and progression-free survivalIn: Leukemia Jg. 20 (2006) Nr. 4, S. 724Online Volltext: dx.doi.org/
-
Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression statusIn: Leukemia Jg. 20 (2006) Nr. 10, S. 1774 - 1782Online Volltext: dx.doi.org/
-
Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemiaIn: Leukemia & Lymphoma Jg. 47 (2006) Nr. 6, S. 1053 - 1061Online Volltext: dx.doi.org/
-
The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemiaIn: Clinical Cancer Research Jg. 12 (2006) Nr. 19, S. 5686 - 5692Online Volltext: dx.doi.org/
-
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemiaIn: Leukemia Jg. 19 (2005) Nr. 5, S. 750 - 758Online Volltext: dx.doi.org/
-
HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemiaIn: Blood Jg. 105 (2005) Nr. 4, S. 1694 - 1698Online Volltext: dx.doi.org/
-
B-cell chronic lymphocytic leukemia with aberrant CD8 expression : genetic and immunophenotypic analysis of prognostic factorsIn: Leukemia & Lymphoma Jg. 45 (2004) Nr. 8, S. 1677 - 1681Online Volltext: dx.doi.org/
-
Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantationIn: European Journal of Haematology Jg. 73 (2004) Nr. 1, S. 1 - 9Online Volltext: dx.doi.org/
-
Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemiaIn: Leukemia Jg. 18 (2004) Nr. 11, S. 1816 - 1823Online Volltext: dx.doi.org/
-
CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cellsIn: Blood Jg. 102 (2003) Nr. 6, S. 2146 - 2155Online Volltext: dx.doi.org/
-
Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemiaIn: Blood Jg. 101 (2003) Nr. 7, S. 2748 - 2755Online Volltext: dx.doi.org/
-
Salvage chemotherapy according to the ASHAP protocol : a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomasIn: Annals of Hematology Jg. 82 (2003) Nr. 8, S. 481 - 486Online Volltext: dx.doi.org/
-
The CC genotype of the C825T polymorphism of the G protein beta3 gene (GNB3) is associated with a high relapse rate in patients with chronic lymphocytic leukaemiaIn: Leukemia & Lymphoma Jg. 44 (2003) Nr. 10, S. 1739 - 1743Online Volltext: dx.doi.org/
-
ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemiaIn: Leukemia Jg. 17 (2003) Nr. 12, S. 2426 - 2434Online Volltext: dx.doi.org/
-
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemiaIn: Leukemia Jg. 16 (2002) Nr. 1, S. 30 - 35Online Volltext: dx.doi.org/
-
Differential expression of chemokine receptors in B cell malignanciesIn: Leukemia Jg. 15 (2001) Nr. 5, S. 752 - 756
-
Effects of vascular endothelial and platelet-derived growth factor receptor inhibitors on long-term cultures from normal human bone marrowIn: Growth Factors Jg. 19 (2001) Nr. 1, S. 1 - 17Online Volltext: dx.doi.org/
-
Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+ haemopoietic cellsIn: Leukemia Jg. 14 (2000) Nr. 9, S. 1652 - 1660
-
Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytesIn: British Journal of Haematology Jg. 108 (2000) Nr. 3, S. 488 - 495Online Volltext: dx.doi.org/
-
Intercellular communication between bone marrow stromal cells and CD34+ haematopoietic progenitor cells is mediated by connexin 43-type gap junctionsIn: British Journal of Haematology Jg. 111 (2000) Nr. 2, S. 416 - 425Online Volltext: dx.doi.org/
-
Ibrutinib + bortezomib + R‐CHOP for higher‐risk DLBCL : Feasibility, efficacy and molecular predictorsIn: Hematological Oncology Jg. 41 (2023) Nr. S2, 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023, S. 424 - 425Online Volltext: dx.doi.org/ (Open Access)
-
Treatment regimens in high-risk CLL
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 19Online Volltext: dx.doi.org/ (Open Access) -
Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood Jg. 140 (2022) Nr. Supplement 1, S. 834 - 836Online Volltext: dx.doi.org/ (Open Access) -
Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma : Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans,In: Blood Jg. 140 (2022) Nr. Supplement 1: 64th Annual Meeting, S. 2283 - 2285Online Volltext: dx.doi.org/ (Open Access) -
Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients : The Phase III GMMG-HD7 Trial
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood Jg. 138 (2021) Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 463 - 465Online Volltext: dx.doi.org/ (Open Access) -
Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma : Results from the Randomized Phase III GMMG-HD6 Trial
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood Jg. 138 (2021) Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 486 - 488Online Volltext: dx.doi.org/ (Open Access) -
Long-term Follow-Up in Patients with Stage IAE Orbital Lymphoma and Radiotherapy with Photons : Monocentric ResultsIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 58 - S59
-
Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma : An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood Jg. 138 (2021) Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 3792 - 3795Online Volltext: dx.doi.org/ (Open Access) -
Severe infections and early death during novel agent-based induction therapy in newly-diagnosed, transplant-eligible multiple myeloma
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 21Online Volltext: dx.doi.org/ (Open Access) -
Anti-leukemic activity through CDK9 inhibition in T-cell prolymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 218Online Volltext: dx.doi.org/ (Open Access) -
Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma : Results from the phase III GMMG-HD4 and -MM5 trials
17th International Myeloma Workshop ; September 12-15, 2019, Boston, MA, USA,In: Clinical Lymphoma, Myeloma & Leukemia Jg. 19 (2019) Nr. 10, Suppl., S. e43Online Volltext: dx.doi.org/ -
Pomalidomide + Bortezomib + Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma : Subanalysis of OPTIMISMM
17th International Myeloma Workshop ; September 12-15, 2019, Boston, MA, USA,In: Clinical Lymphoma, Myeloma & Leukemia Jg. 19 (2019) Nr. 10, Suppl., S. e32 - e33Online Volltext: dx.doi.org/ -
Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma : Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant
61st ASH (American Society of Hematology) Annual Meeting & Exposition; Dec 07 - 10 2019; Oralndo, USA,In: Blood Jg. 134 (2019) Nr. Supplement_1, S. 3120 - 3120Online Volltext: dx.doi.org/ (Open Access) -
The MP0250-CP201 Mirror Study : A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs
61st ASH (American Society of Hematology) Annual Meeting & Exposition; Dec 07 - 10 2019; Oralndo, USA,In: Blood Jg. 134 (2019) Nr. Supplement_1: Annual Meeting Abstracts, S. 1899 - 1899Online Volltext: dx.doi.org/ (Open Access) -
Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW) : Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)
61st ASH Annual Meeting and Exposition, 07.-10.12.2019, Orlando, FL,In: Blood Jg. 134 (2019) Nr. Supplement_1, S. 343Online Volltext: dx.doi.org/ (Open Access) -
Unmaintained remission after discontinuation of kinase inhibitor treatment in chronic lymphocytic leukemia: an observational cohort
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 18Online Volltext: dx.doi.org/ (Open Access) -
Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma : The Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1: 60th ASH Annual Meeting Abstracts, S. 448 - 448Online Volltext: dx.doi.org/ (Open Access) -
Four versus two years of Rituximab maintenance (R-maintenance) following Bendamustine plus Rituximab (B-R): initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 251Online Volltext: dx.doi.org/ (Open Access) -
Gain of STAT3/5 locus is a recurrent cryptic aberration in T-cell prolymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 318Online Volltext: dx.doi.org/ (Open Access) -
MP0250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previoulsy Exposed to Proteasome Inhibitors and Immunomodulatory Drugs
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1: 60th ASH Annual Meeting Abstracts, S. 1980 - 1980Online Volltext: dx.doi.org/ (Open Access) -
Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma : A Subgroup Analysis of the Phase 3 Optimismm Trial
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1: 60th ASH Annual Meeting Abstracts, S. 3278 - 3278Online Volltext: dx.doi.org/ (Open Access) -
Pomalidomide, cyclophosphamide and dexamethasone in case of suboptimal response to pomalidomide and dexamethasone alone in relapsed and/or refractory multiple myeloma : Final results of the GMMG-PERSPECTIVE trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 133 - 134Online Volltext: dx.doi.org/ (Open Access) -
Preliminary data of the ongoing open-label, single-arm phase II study of MP0250 in combination with bortezomib plus dexamethasone in patients with relapsed refractory multiple myelomaIn: Haematologica / The Hematology Journal Jg. 103 (2018) Nr. Suppl. 1,
-
The DNA-methylation status of BCL11B in T-Cell-Large Granular Lymphocytic Leukemia - a diagnostic target
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 317Online Volltext: dx.doi.org/ (Open Access) -
Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1: 60th ASH Annual Meeting Abstracts, S. 4485 - 4485Online Volltext: dx.doi.org/ (Open Access) -
CDK9 Inhibition with LDC526 Is an Effective Treatment for T-Cell Prolymphocytic Leukemia (T-PLL) in VitroIn: Blood Jg. 130 (2017) Nr. Suppl. 1, S. 1262Online Volltext: dx.doi.org/
-
Epigenetic analyses of T-cell large granular lymphocytic leukemia identify differentially methylated enhancer regions leading to deregulation of gene interactionsIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3, Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts, S. 109 - 110Online Volltext: dx.doi.org/
-
Positron-emission tomography-guided therapy of aggressive non-Hodgkin lymphomas -final results of the PETAL trialIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3, S. 202 - 203Online Volltext: dx.doi.org/
-
Genomic profiling of T-cell Prolymphocytic Leukemia (T-PLL) identifies novel recurrent mutations in SAMHD1 and PTPRC
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Leipzig, 14.–18. Oktober 2016,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 3, S. 238 - 238Online Volltext: dx.doi.org/ -
Establishment of a real-time PCR assay to quantify the size of a NOTCH1 mutated subclone in chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 60Online Volltext: dx.doi.org/ -
Expansion of a stimulatory natural killer receptor NKp80-expessing CD8+T-cell subset in chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 191Online Volltext: dx.doi.org/ -
Percentage of smudge cells on routine blood smears predict time to first treatment and overall survival in patients with Binet stage A chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 139Online Volltext: dx.doi.org/ -
Preclinical testing of a novel CDK9 inhibitor in chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 195 - 196Online Volltext: dx.doi.org/ -
Progranulin plasma levels predict time to first treatment and overall survival in chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 196 - 196Online Volltext: dx.doi.org/ -
Role of the acid sphingomyelinase in hematogenous tumor metastasis in a mouse model
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Basel, 30.09.–04.10. 2011,In: Onkologie Jg. 34 (2011) Nr. Suppl. 6, S. 46Online Volltext: dx.doi.org/ -
Association of HLA-G Haplotype Risk Model with Treatment Free Survival In Chronic Lymphocytic Leukemia PatientsIn: Blood Jg. 116 (2010) Nr. 21, S. 1002 - 1003Online Volltext: dx.doi.org/
-
Association of HLA-G haplotype risk model with treatment free survival in chronic lymphocytic leukemia patients
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, Berlin, Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 45Online Volltext: dx.doi.org/ -
Comparing the pharmacological effects of the novel Locked Nucleic Acid (LNA) modified antisense Bcl-2 inhibitor SPC2996 and G3139 (oblimersen) in preclinical models of chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 184Online Volltext: dx.doi.org/ -
Expanded CD8(+) T-cells of murine and human B-CLL are driven into a senescent KLRG1(+) effector memory phenotypeIn: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 201Online Volltext: dx.doi.org/
-
Expanded CLL CD8(+) T-Cells Are Driven Into a Senescent KLRG1(+) Effector Memory PhenotypeIn: Blood Jg. 116 (2010) Nr. 21, S. 403
-
Heterogeneous Interactions of Leukemic and Control Bone Marrow Stroma Cells with an AML Cell Line and AML Leukemic BlastsIn: Blood Jg. 116 (2010) Nr. 21, S. 460Online Volltext: dx.doi.org/
-
Heterogeneous interactions of leukemic and control bone marrow stroma cells with an AML cell line and AML leukemic blasts
Deutsche, Österreichische und Schweizerische Gesellschaften für Hämatologie und Onkologie Jahrestagung, Berlin, Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 235Online Volltext: dx.doi.org/ -
High soluble MICA levels are associated to MICA-129 val/val genotypes and poor treatment free survival in chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 41 - 42Online Volltext: dx.doi.org/ -
Investigating the interaction of leukemic B and non-malignant T cells in a novel Rag2-/gamma c-/--xenograft model of human chronic lymphocytic leukemia (CLL)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 202Online Volltext: dx.doi.org/ -
Outpatient management of acute myeloid leukemia after intensive consolidation chemotherapy is feasible and reduces hospital treatment costsIn: Oncology Jg. 33 (2010) Nr. 12, S. 658 - 664Online Volltext: dx.doi.org/
-
Polyclonal B-Cell activation and Expansion of Monoclonal B Cells in the Peripheral Blood of Patients with Chronic Hepatitis CIn: Hepatology Jg. 52 (2010) Nr. Suppl. 1, S. 740AOnline Volltext: dx.doi.org/
-
Prevalence of B cell lymphoproliferative disorders in patients with chronic hepatitis C (CHC)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010, pp 109–206,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 157Online Volltext: dx.doi.org/ -
Prevalence of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Light-Chain MGUS (LCMGUS) In a Metropolitan Area In GermanyIn: Blood Jg. 116 (2010) Nr. 21, 4037Online Volltext: dx.doi.org/
-
Role of the antigenic stimulation in the pathogenesis of chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 39Online Volltext: dx.doi.org/ -
The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 42Online Volltext: dx.doi.org/ -
Large Granular Lymphocyte LeukemiaIn: Chronic Lymphocytic Leukemia / Hallek, Michael; Eichhorst, Barbara; Catovsky, Daniel (Hrsg.) 2019, S. 167 - 179Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma : a multicohort analysis from phase III trials
18th International Myeloma Workshop ; September 8 - 11, 2021, Vienna, Austria,In: Clinical Lymphoma, Myeloma & Leukemia Jg. 21 (2021) Nr. Suppl. 2, S. S133 - S134Online Volltext: dx.doi.org/